Sun Pharma initiates trial for deuruxolitinib in severe alopecia areata in Japan
A clinical trial is underway to assess deuruxolitinib's efficacy and safety in Japanese adults with severe alopecia areata.
Asset / Drug
Drug and asset intelligence for deuruxolitinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.